Helomics Launches Precision Cellular Analytical Platform (PCAP) Expanding Their Comprehensive Tumor Profiling Offering To Patients, Physicians And Life Science Industry

Comprehensive Tumor Profiling with PCAP™ System is the key to Elucidation of Tumor Biology and Cancer Patient Outcomes

PITTSBURGH & LONDON--(BUSINESS WIRE)--Helomics™ Corporation, a privately-held personalized healthcare company that provides comprehensive tumor profiling utilizing proprietary live cell and fixed cell products and services, announced today that it will be launching, in April, the 4^th generation of the company’s comprehensive tumor profiling offering to include their “Precision Cellular Analytical Platform™” or PCAP™.

“The ability to analyze a patient’s proliferating tumor cells through the analytical tests that comprise our proprietary PCAP platform enables us to examine tumor biology more thoroughly while allowing us to augment that analysis with genomics and proteomics information, providing a more comprehensive tumor profile.”

The PCAP system will be used to further enhance Helomics’ research, industry and clinical product offerings including the company’s oncology treatment marker, ChemoFx^®. The flexible nature of PCAP will allow Helomics to better collaborate with partners in pharma, diagnostics, biotech, academia, and government to identify and develop new treatment markers and companion diagnostics, as well as new anti-cancer therapies. Additionally, the PCAP system will expand the company’s reach into nutrigenomics and proteomics in the wellness and prevention markets.

An information video on PCAP is available at the following link: http://bit.ly/18yoN6E

Neil J. Campbell, President & CEO of Helomics said “The ability to analyze a patient’s proliferating tumor cells through the analytical tests that comprise our proprietary PCAP platform enables us to examine tumor biology more thoroughly while allowing us to augment that analysis with genomics and proteomics information, providing a more comprehensive tumor profile.”

About Precision Cellular Analytical Platform (PCAP™)

The PCAP™ platform consists of a suite of tests that allows Helomics to profile gene regulation, protein expression, and cellular morphology over time. The core of the platform is Helomics’ ability to grow primary human tumors in tissue culture. Physicians and researchers send tumor specimens to Helomics who utilize proprietary methods to grow the patient’s tumor. This permits the temporal analysis of gene and protein expression associated with tumor cell proliferation, tumor cell death, drug response, and/or drug toxicity. Helomics ability to grow primary human tumors in culture has been meticulously refined for over 15 years and is currently in its 4^th generation of tumor biology elucidation.

About ChemoFx®

ChemoFx® is a treatment marker for cancer patients. As part of the PCAP™ System, ChemoFx® quantifies an individual gynecologic cancer patient’s probable outcome when treated with various chemotherapeutic and biologic therapies —providing both degree of efficacy and a personalized comprehensive profile of the patient’s tumor. ChemoFx® informs medical practice and allows physicians and care-giver teams to optimize standards of care. ChemoFx® provides valuable insights that help physicians’ select effective treatments and give both physicians and patients an edge against gynecologic cancer.

By testing multiple chemotherapies on a patient’s cancer cells before treating a cancer patient, ChemoFx® helps determine the chemotherapies that are more likely to be effective and helps guide the physician away from therapies that are more likely to be ineffective - giving patients a powerful advantage in the fight against gynecologic cancers.

Multiple ChemoFx studies demonstrate improvement in both progression-free and overall survival for both primary as well as platinum-sensitive and platinum-resistant recurrent ovarian cancer patients when treated with agents identified as effective by ChemoFx.

About Helomics Corporation, Inc.

Helomics is a comprehensive personalized healthcare company, bringing the next generation of diagnostics to the oncology field. Helomics is dedicated to improving patient outcomes by providing a personalized comprehensive tumor profile utilizing a proprietary set of laboratory platforms that leverage both live and fixed cellular based analysis allowing physicians to characterize malignant tumors on a personalized basis. Helomics’ novel molecular and cellular markers and bioinformatics services support treatment decisions by providing vital information based on the specific biological processes of each individual’s cancer.

Helomics is headquartered in Pittsburgh, Pennsylvania where the company maintains two CLIA-certified laboratories. For more information please visit: www.helomics.com.

Forward-Looking Statements

This release may contain forward-looking statements that involve risks and uncertainties. Market conditions and important factors that could cause actual results to differ materially from those communicated in any forward-looking statements information disclosed in presentations, conference calls or other public venues. We do not intend to update any forward-looking statements after the date of this press release.

Help employers find you! Check out all the jobs and post your resume.